Oncology Care Coordination AI: CMS Payment Models, Prior Authorization Burden, and Automated Cancer Care Pathways

Published February 25, 2026 Reading time ~12 min Category Oncology Operations

Cancer care is among the most administratively complex segments of healthcare. A single oncology patient may require coordination across medical oncology, radiation oncology, surgical oncology, pathology, radiology, infusion services, and supportive care — all subject to prior authorization requirements that consume 40 hours per physician per week according to AMA survey data. CMS oncology alternative payment models add quality reporting requirements on top of that administrative burden. AI coordination platforms purpose-built for oncology can reclaim physician and care coordinator time while improving care pathway adherence and reducing treatment delays.

40 hrs/wk

Average physician time spent on prior authorization per week (AMA 2023 Prior Auth Survey)

The AMA's 2023 Prior Authorization Physician Survey found that practices complete an average of 43 prior authorization requests per physician per week. 94% of physicians report that prior auth burdens delay care access. In oncology, authorization delays for chemotherapy regimens, radiation therapy, and imaging studies can directly affect treatment outcomes — delays of more than 1-2 weeks in initiating systemic therapy are associated with measurable survival impacts in multiple cancer types.

CMS Oncology Payment Models

CMS Oncology Care Model (OCM): 2016–2022

$1.5B+ in Medicare Spending Under Model

Program: CMS Oncology Care Model (OCM)
Period: July 2016 – June 2022
Participants: 140+ oncology practices, 16 payer partners
Structure: Episode-based payment (6-month episodes around chemotherapy) with performance-based risk sharing
Key Requirements: Navigation services, 24/7 access to care, care plan documentation, MIPS reporting integration
Successor: Enhancing Oncology Model (EOM), launched July 2023

CMS Enhancing Oncology Model (EOM): 2023–Present

6-Month Episode-Based Payment Model

Program: Enhancing Oncology Model (EOM)
Launch: July 1, 2023
Cancer Types Covered: Breast, CLL/SLL, lung, lymphoma, multiple myeloma, prostate, uterine cancers
Payment Structure: Monthly Enhanced Oncology Services (MEOS) payment of $70/beneficiary/month plus performance-based adjustment
AI Opportunity: Automated care plan documentation, navigation service tracking, patient-reported outcome collection

Prior Authorization Burden in Oncology

Oncology prior authorization is uniquely burdensome because cancer treatments are clinically complex, time-sensitive, and require frequent reauthorization as regimens are modified. The AMA's survey data breaks down the burden by specialty — oncology practices report among the highest prior auth volumes in medicine:

Chemotherapy regimen authorization: Each new regimen requires payer-specific clinical criteria review, often requiring submission of pathology reports, genomic testing results, and staging documentation
Step therapy requirements: Many payers require sequential treatment with first-line agents before authorizing targeted or immunotherapy regimens — creating authorization loops that delay molecularly matched treatment
Imaging reauthorization: PET scans, CT scans, and MRI studies used for staging and treatment response monitoring each require separate authorization, often every 2-4 cycles
Radiation therapy authorization: Complex radiation techniques (SBRT, proton therapy, IMRT) face the highest denial rates at initial authorization — up to 26% denial rate for proton therapy at initial request (ASTRO 2022 survey)

AMA Finding: 34% of physicians report that prior authorization has led to a serious adverse event for a patient in their practice. In oncology, where treatment delays can affect survival outcomes, this statistic reflects a patient safety issue, not merely an administrative inconvenience. AI prior authorization automation that submits complete, criterion-matched requests at the time of ordering reduces initial denial rates and eliminates delay cycles.

AI Capabilities for Oncology Care Coordination

Effective oncology care coordination AI addresses the specific workflow gaps that create administrative burden and treatment delays:

Multi-disciplinary tumor board scheduling: Automated coordination of tumor board case presentations, including specialist availability, imaging pre-fetching, and pathology report aggregation
Treatment regimen prior auth automation: Integration with NCCN guideline databases to auto-populate authorization requests with the specific clinical criteria payers require for each regimen
Infusion scheduling optimization: Coordinating chair time, pharmacy preparation, laboratory draws, and provider availability for complex multi-drug regimens
Symptom monitoring between visits: Automated patient-reported outcome collection (PRO) between appointments, triggering care coordinator outreach when symptoms exceed defined thresholds
Navigation service documentation: Automated documentation of EOM-required navigation services for compliance with CMS model requirements and MEOS payment eligibility

Oncology AI Compliance and Implementation Checklist

Oncology Care Coordination AI Requirements

CMS EOM Navigation Documentation
If participating in the Enhancing Oncology Model, AI must document navigation service delivery in a format meeting CMS data submission requirements. Navigation services are required for MEOS payment eligibility and must be documented with service type, date, and patient identifier.

HIPAA Oncology-Specific PHI Sensitivity
Cancer diagnosis is among the most sensitive categories of PHI. AI communications must apply heightened minimum-necessary standards — appointment reminders should not reveal diagnosis type or treatment modality to third parties. Confirm patient communication preferences and privacy settings before automated outreach.

Prior Auth Submission Completeness Verification
AI prior auth systems must verify submission completeness against payer-specific checklists before submission. Incomplete submissions are the leading cause of initial denial in oncology — AI should flag missing documentation (pathology reports, biomarker results, staging) before submission.

FDA SaMD Classification Review for Clinical AI
If the AI makes or influences clinical decisions (e.g., treatment pathway recommendations, symptom severity scoring that triggers clinical action), it may qualify as Software as a Medical Device (SaMD) under FDA jurisdiction. Clinical decision support AI must comply with the FDA's 2022 CDS guidance and may require 510(k) clearance.

Oncology EHR Integration Complexity
Oncology practices often use oncology-specific EHR modules (Epic Beacon, Elekta, ARIA for radiation) in addition to general EHR systems. AI must integrate with the full technology stack, including pharmacy (chemotherapy order verification), laboratory (CBC monitoring), and radiation planning systems.

Clinical Trial Coordination Compliance
Oncology practices running clinical trials face additional FDA and IRB compliance requirements for patient communication and data handling. AI must not be used for clinical trial participant communication without explicit IRB approval of the AI-assisted communication protocol.

Frequently Asked Questions

How does the CMS Enhancing Oncology Model (EOM) affect AI adoption decisions?

The EOM creates financial incentives for care coordination investment. The $70/beneficiary/month MEOS payment is intended to fund navigation services and care coordination activities — many of which can be supported or enhanced by AI. Practices in the EOM can use MEOS funds to offset AI platform costs when the AI directly supports navigation documentation, patient engagement, and care plan adherence tracking.

Can AI help with oncology prior authorization denials and appeals?

Yes. AI can significantly reduce initial denial rates by submitting complete, criterion-matched authorization requests. For denials, AI can draft peer-to-peer request letters, compile clinical evidence packages supporting appeals, and track appeal status and deadlines. The AMA's 2023 survey found that 61% of overturned denials required physician time for appeals — AI can reduce the physician time required by preparing the documentation package for physician review and signature.

What are the HIPAA considerations specific to oncology AI?

Oncology AI must apply heightened privacy protections for cancer diagnosis information. Specific considerations: (1) Appointment reminders must not reveal cancer type or treatment in unencrypted communications; (2) Patient-reported outcome collection via AI must be through HIPAA-compliant channels with documented BAAs; (3) Genomic and biomarker data used for treatment matching has additional sensitivity — some states (California, New York) have specific genetic privacy laws; (4) Clinical trial data is subject to both HIPAA and FDA 21 CFR Part 11 requirements for electronic records.

How does AI improve chemotherapy infusion scheduling?

Infusion scheduling AI coordinates the interdependent constraints of oncology treatment: chair availability, pharmacy preparation lead time, laboratory result availability before treatment, nursing staffing, and physician oversight scheduling. AI optimization of infusion scheduling reduces patient wait times by an average of 23 minutes per visit in practices using scheduling AI (ASCO 2023 quality improvement data) and improves chair utilization from typical 65-70% to 82-88% utilization.

Is oncology AI covered as a medical device by the FDA?

It depends on function. Administrative AI (scheduling, communication, prior auth) is not an FDA-regulated medical device. Clinical AI that analyzes imaging, pathology, or genomic data to inform diagnosis or treatment selection is likely subject to FDA oversight as Software as a Medical Device (SaMD). The FDA's 2022 Clinical Decision Support guidance provides the analytical framework — if the AI's output is intended for clinical decision-making and requires clinical expertise to interpret, it likely requires FDA review. Consult with regulatory counsel before deploying clinical oncology AI.

Coordinate Every Oncology Patient Touchpoint with Claire

From prior authorization automation to EOM navigation documentation, Claire integrates with Epic Beacon, ARIA, and oncology-specific workflows — with full HIPAA compliance.

Book a Demo See How It Works